Publish in OALib Journal

ISSN: 2333-9721

APC: Only $99


Search Results: 1 - 10 of 63 matches for " Dinie Najwa Bero "
All listed articles are free for downloading (OA Articles)
Page 1 /63
Display every page Item
Tamarind Seed Extract Enhances Epidermal Wound Healing
Mohd Yusof bin Mohamad,Haris B Akram,Dinie Najwa Bero,Mohammad Tariqur Rahman
International Journal of Biology , 2011, DOI: 10.5539/ijb.v4n1p81
Abstract: Traditional healing power of tamarind fruits and the established antioxidant activity of the seeds drive the present study. Wound healing efficiency of tamarind seed was evaluated. Different solvents: phosphate buffer saline (PBS), water, methanol and ethanol were used to prepare the extract. Circular wound was inflicted on the nape. 10 μl of 5 μg/ml of extract was applied topically twice daily. Wound area was measured using Adobe Photoshop C3 Extended version and the percentage of wound reduction was calculated. PBS extract treatment induced complete wound healing in shortest period (10 days) while water extract, methanol extract and Solcoseryl ointment treatment induced complete wound healing in 11 days and control groups without any treatment took 14 days to heal. Phytochemical screening and Bradford method for protein quantification reveals the presence of alkaloid, saponin and tannin in all samples except PBS extract which tested negative to tannin. Flavonoid tested positive in methanol and ethanol extracts.
Students’ and Instructors’ Perceptions of Turnitin: A Plagiarism Deterrent?  [PDF]
Najwa Saba Ayon
Creative Education (CE) , 2017, DOI: 10.4236/ce.2017.813141
Abstract: Academicians consider plagiarism a major threat to academia. To combat that threat, a lot of universities, including the researcher’s university, have been using Turnitin. It is believed that this software is likely to deter students’ plagiarism. The aim of this study is, therefore, to investigate1) the impact of Turnitin on students’ plagiarism from the perspectives of both students and instructors in a private Lebanese English-speaking university and 2) the reasons that push students to plagiarize. A concurrent mixed-methods design is employed, and different data collection methods are used. The data are analyzed quantitatively and qualitatively. Findings reveal that although a lot of the participants perceive Turnitin as a good deterrent to plagiarism, it did not completely inhibit it. The findings also reveal that not all instructors were committed enough to use Turnitin in their courses. Some of the reasons for plagiarism that the participants named are lack of citation skills, laziness, and indifference among students to abide by ethical writing norms.Besides reinforcing the use of Turnitin among all instructors, the researcher recommends that students’ writing and citation skills be improved and that students be helped to become more ethical writers.
The Bigger Picture: Commentary on a Documentary in the Making.
Najwa Saad.
Nebula , 2005,
Big Pharma (The Play)
Lisa Bero
PLOS Biology , 2012, DOI: 10.1371/journal.pbio.0050104
Big Pharma (The Play)
Lisa Bero
PLOS Biology , 2007, DOI: 10.1371/journal.pbio.0050104
Refined total variation bounds in the multivariate and compound Poisson approximation
Bero Roos
Mathematics , 2015,
Abstract: We consider the approximation of a convolution of possibly different probability measures by (compound) Poisson distributions and also by related signed measures of higher order. We present new total variation bounds having a better structure than those from the literature. A numerical example illustrates the usefulness of the bounds. The proofs use arguments from Kerstan (Z. Wahrscheinlichkeitstheorie und Verw. Gebiete 2 (1964) 173-179) and Roos (J. Multivariate Anal. 69 (1999) 120-134) in combination with new smoothness inequalities, which could be of independent interest.
Closeness of convolutions of probability measures
Bero Roos
Mathematics , 2008,
Abstract: We derive new explicit bounds for the total variation distance between two convolution products of $n$ probability distributions, one of which having identical convolution factors. Approximations by finite signed measures of arbitrary order are considered as well. We are interested in bounds with magic factors, i.e. roughly speaking $n$ also appears in the denominator. Special emphasis is given to the approximation by the $n$-fold convolution of the arithmetic mean of the distributions under consideration. As an application, we consider the multinomial approximation of the generalized multinomial distribution. It turns out that here the order of some bounds given in Roos (2001) and Loh (1992) can significantly be improved. In particular, it follows that a dimension factor can be dropped. Moreover, better accuracy is achieved in the context of symmetric distributions with finite support. In the course of proof, we use a basic Banach algebra technique for measures on a measurable Abelian group. Though this method was already used by Le Cam (1960), our central arguments seem to be new. We also derive new smoothness bounds for convolutions of probability distributions, which might be of independent interest.
On Bobkov's approximate de Finetti representation via approximation of permanents of complex rectangular matrices
Bero Roos
Mathematics , 2012,
Abstract: Bobkov (J. Theoret. Probab. 18(2) (2005) 399-412) investigated an approximate de Finetti representation for probability measures, on product measurable spaces, which are symmetric under permutations of coordinates. One of the main results of that paper was an explicit approximation bound for permanents of complex rectangular matrices, which was shown by a somewhat complicated induction argument. In this paper, we indicate how to avoid the induction argument using an (asymptotic) expansion. Our approach makes it possible to give new explicit higher order approximation bounds for such permanents and in turn for the probability measures mentioned above.
Synergistic Combination of Carbapenems and Colistin against P. aeruginosa and A. baumannii  [PDF]
Ziad Daoud, Najwa Mansour, Khalil Masri
Open Journal of Medical Microbiology (OJMM) , 2013, DOI: 10.4236/ojmm.2013.34038
Abstract: Background: Intubated patients are particularly at risk of developing infections caused by these pathogens, specifically, P. aeruginosa and A. baumannii. In the past fifteen years, Carbapenems were known to be the drugs of choice for these bacteria. With the increase in the use and misuse of antibiotics, these bacteria became highly resistant, and almost all available antibiotics, including Carbapenems, became inefficient. Synergistic combination therapy may be a useful strategy in slowing as well as overcoming the emergence of resistance. The aim of this study was to evaluate the anti-bacterial activity on P. aeruginosa and A. baumannii of the combination of two antibiotics: Colistin and a Carbapenem (Meropenem or Imipenem). Methods: The antibacterial activity was assessed by determining the MIC. Then, the effect of combining the antibiotics was studied using the Checkerboard Technique described by White et al., 1996. The Fractional Inhibitory Concentration (FIC) for each strain was then calculated and classified as synergy, additive, indifference or antagonism. 11 strains of A. baumannii and 11 strains of P. aeruginosa were tested in the presence of Meropenem combined with Colistin or Imipenem combined with Colistin. Results: For the combination of Meropenem and Colistin, 6 strains of A. baumannii and 3 strains of P. aeruginosa showed synergy while 5 strains of A. baumannii and 7 strains of P. aeruginosa showed additive effect, only 1 strain of P. aeruginosa showed antagonism. For Imipenem and Colistin, only 1 strain of A. baumannii and 3 strains of Pseudomonas showed synergy while 8 strains of Acinetobacter and 8 strains of Pseudomonas showed additive effect. Conclusion: The “in vitro” combination Colistin-Carbapenem is associated with an improvement in MIC. In the majority of the cases, this improvement suggests a synergistic combination or an additive effect.
Factors Associated with Results and Conclusions of Trials of Thiazolidinediones
Gail Rattinger, Lisa Bero
PLOS ONE , 2009, DOI: 10.1371/journal.pone.0005826
Abstract: Background When a sponsor funds a study of two competing drugs in a head-to-head comparison, the results and conclusions are likely to favor the sponsor’s drug. Thiazolidinediones, oral medications used for the treatment of type 2 diabetes, are one of the most costly choices of oral anti-diabetic medications, yet they do not demonstrate clinically relevant differences in achieving lower glycosylated hemoglobin levels compared to other oral antidiabetic drugs. Our aim is to examine associations between research funding source, study design characteristics aimed at reducing bias, and other factors with the results and conclusions of randomized controlled trials (RCTs) of thiazolidinediones compared to other oral hypoglycemic agents. Methods and Findings This is a cross-sectional study of 61 published RCTs comparing a thiazolidinedione (glitazone) to another anti-diabetic drug or placebo for treatment of type 2 diabetes. Data on study design characteristics, funding source, author’s financial ties, results for primary outcomes, and author conclusions were extracted. Univariate logistic regression identified associations between independent variables and results and conclusions that favored the glitazone. Of the RCTs, 59% (36/61) were funded by industry, 39% (24/61) did not disclose any funding. Common study design weaknesses included inadequate blinding and lack of concealment of allocation. Trials that reported favorable glycemic control results for the glitazone were more likely to have adequate blinding (OR (95% CI) = 5.42 (1.46, 21.19), p = 0.008) and have a corresponding author with financial ties to the glitazone manufacturer (OR (95% CI) = 4.12 (1.05, 19.53); p = 0.04). Trials with conclusions favoring the glitazone were less likely to be funded by a comparator drug company than a glitazone company (OR (95% CI) = 0.026 (0, 0.40), p = 0.003) and less likely to be published in journals with higher impact factors (OR (95% CI) = 0.79 (0.62, 0.97), p = 0.011). One limitation of our study is that we categorized studies as funded by industry based on each article’s disclosure which could underestimate the number of industry sponsored studies and personal ties of investigators. Additionally, our study did not include any head-to-head comparisons of one glitazone to another. Conclusions Published RCT comparisons of glitazones with other anti-diabetic drugs or placebo are predominantly industry supported and this support, as well as the financial ties of study authors, appears to be associated with favorable findings.
Page 1 /63
Display every page Item

Copyright © 2008-2017 Open Access Library. All rights reserved.